Notable Labs brings on 2 development executives ahead of its first blood cancer trials

Its first program targets B-cell malignancies that have relapsed after antibody or CAR-T immunotherapies, with a clinical trial set to start later this year at The University of Kansas Cancer Center. (Pixabay)

After launching its first in-house R&D program last month, cancer drug-testing startup Notable Labs has brought on two biopharma executives to take charge of its clinical operations and drug development work.

Incyte’s Hiroomi Tada joined as chief medical officer, while Aquinox’s Lloyd Mackenzie will serve as chief development officer.  

Tada was most recently vice president of targeted therapies and translational sciences at Incyte, where he helped guide the company’s oncology portfolio. Before that, he was a medical director for clinical development in oncology at GlaxoSmithKline, and a director of clinical research at AstraZeneca.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Mackenzie will help Notable identify drug development opportunities. He was most recently chief operating officer and VP of R&D at Aquinox, after 11 years at the company. There, he helped oversee clinical and nonclinical operations, including chemistry, manufacturing and controls, as well as quality assurance. Prior to Aquinox, he was a research scientist at QLT and Inflazyme Pharmaceutical.

RELATED: Notable Labs nets $10M for personalized cancer treatment tech

“I’ve been watching the company since it launched, and I was really excited to have the opportunity to come on board to help shape the direction of its growth,” Mackenzie said in a statement.

The company’s automated laboratory works to evaluate thousands of drug combinations on cancer cells and compares them to healthy cells, to prioritize the most specifically active drugs for treatment. Its first validation trials have focused on blood cancers.

"Notable's testing platform is truly a precision medicine approach to individualize cancer care and has the potential to change the way treatment decisions are made," Tada said.

Its first drug development program, ND-1000, targets adult and pediatric blood cancers, specifically B-cell malignancies that relapse after antibody treatments or CAR-T immunotherapies. Notable plans to begin its first clinical trial for ND-1000 later this year at The University of Kansas Cancer Center, in partnership with the university’s Institute for Advancing Medical Innovation.

The Foster City, California-based company has also opted to donate the commercial rights to its future price, manufacturing and distribution in pediatric leukemia to the nonprofit Cures Within Reach, which works to repurpose drugs, devices and research toward additional unmet needs.

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.